Tag:
India
Latest Headlines
Latest Headlines
GlaxoSmithKline, Ranbaxy among hardest hit in Indian price cuts
New price controls are on their way in India, and brokerage house HSBC has identified which companies are most likely to suffer from the cuts. Meanwhile, regulators are once again looking at new hurdles to foreign investment, inspired by another round of pharma dealmaking.
Indian rotavirus vax set to undercut GSK and Merck
Having committed to offering its rotavirus vaccine--Rotavac--for $1 a dose in 2011, Indian vaccine manufacturer Bharat Biotech has now presented positive Phase III data that compares favorably to currently available rotavirus vaccines.
Unhappy with price caps at home, Indian drugmakers eye more U.S. growth
It's no big secret that international drugmakers are miffed at India. Revoking a few drug patents and overriding others will do that. But India's own pharma companies have their own beef with government policy--namely government pricing policies.
Biocon's CRO now largest in India
India's Biocon reported a huge fiscal year for its CRO arm, growing 36% over the previous year and becoming the largest clinical research provider in the country, the company said.
CardioDx reaches to India with Core partnership
CardioDx, a 2012 Fierce 15 winner, has partnered with India's Core Diagnostics to distribute its coronary artery disease test in the country's burgeoning market.
Panacea Biotec accused of selling expired vaccines
India's government wants the country to become the world's preeminent low-cost vaccine supplier, but it will first have to overcome problems of its own making.
South Africa follows India's lead with proposed drug-patent reforms
South Africa plans to revamp its intellectual-property laws to make it more difficult for pharma companies to win protection for new versions of older drugs. The move comes soon after India's top court backed strict requirements for drug patents.
FDA says data-mining can help find highest risk manufacturers
The drug manufacturing supply chain is complex and global, making it harder for the FDA to keep an eye out for bad players and dangerous products. The vast amount of active pharmaceutical ingredients come from low-cost countries like India and China.
Ishrak: Medtronic has a keen eye on India
Medtronic CEO Omar Ishrak has made no secret of how important emerging markets are to his company's growth, and India's swelling population and expanding medical access are key to the device giant's future, he said.
Indian clinical trials plunge amid increased scrutiny
India's government is struggling to crack down on loosely regulated clinical trials that have killed hundreds of patients around the country, and while it's unclear if its efforts have made the process safer, they've certainly slowed things down.
